Reading summary: the results show that the median time of virus clearance in the treatment group is shorter, the median (interquartile distance) is 4 days (2.5-9 days), while the control group is 11 days (8-13 days), there is significant difference between the two groups.
“The virus was cleared in 4 days and the safety tolerance was good.” The results of a novel coronavirus treatment for new coronavirus pneumonia (COVID-19) patients were published in the press conference of the joint research and defense mechanism of the Ministry of science and technology. The novel coronavirus (Favipiravir) may be effective in alleviating the development of new coronavirus pneumonia by accelerating viral clearance.
The study was carried out by the National Center for drug engineering and technology for emergency prevention and control and Liu Lei and Liu Yingxia, the third people’s Hospital of Shenzhen. 35 patients with novel coronavirus pneumonia who met the criteria were treated with the treatment of 3200mg (first days, 2~14 days, 1200mg/d, 2 times), and the course of treatment was to remove the virus or for 14 days.
A novel coronavirus pneumonia (Ritonavir Tablets), which was matched with age, gender and disease severity, was also enrolled in 45 patients with new crown pneumonia treated with 400mg/100mg (2 times a day). The median time from administration to virus clearance, the improvement rate and safety of chest imaging on the 14th day of treatment were compared between the two groups.
The results showed that the median time of virus clearance in the treatment group was shorter, the median time (interquartile distance) was 4 days (2.5-9 days), while that in the control group was 11 days (8-13 days)
In 2014, it was approved to be listed in Japan. Zhang Xinmin, the group leader of the research team of the joint prevention and control mechanism of the State Council, once mentioned at the press conference of the joint prevention and control mechanism of the State Council that fabiravir is a broad-spectrum antiviral drug, which is an overseas listed drug for treating influenza, and plays an antiviral role by inhibiting the replication and transcription of virus genome. The novel coronavirus pneumonia was not found to have obvious adverse reactions in clinical research.